With Bristol-Myers Squibb Co. (BMS) as well as Roche AG and Astrazeneca plc offering new data at the World Conference on Lung Cancer in Denver, analysts were hard pressed to pick the best wager, though one survey of people on the buy side suggested that they found BMS's combination therapy most impressive.